{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:10:20Z","timestamp":1792782620593,"version":"4.5.0"},"reference-count":146,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,1,18]],"date-time":"2021-01-18T00:00:00Z","timestamp":1610928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,18]],"date-time":"2021-01-18T00:00:00Z","timestamp":1610928000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Projekt DEAL"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Systemic forms of amyloidosis affecting the heart are mostly light-chain (AL) and transthyretin (ATTR) amyloidoses. The latter is caused by deposition of misfolded transthyretin, either in wild-type (ATTRwt) or mutant (ATTRv) conformation. For diagnostics, specific serum biomarkers and modern non-invasive imaging techniques, such as cardiovascular magnetic resonance imaging (CMR) and scintigraphic methods, are available today. These imaging techniques do not only complement conventional echocardiography, but also allow for accurate assessment of the extent of cardiac involvement, in addition to diagnosing cardiac amyloidosis. Endomyocardial biopsy still plays a major role in the histopathological diagnosis and subtyping of cardiac amyloidosis. The main objective of the diagnostic algorithm outlined in this position statement is to detect cardiac amyloidosis as reliably and early as possible, to accurately determine its extent, and to reliably identify the underlying subtype of amyloidosis, thereby enabling subsequent targeted treatment.<\/jats:p>","DOI":"10.1007\/s00392-020-01799-3","type":"journal-article","created":{"date-parts":[[2021,1,18]],"date-time":"2021-01-18T00:02:42Z","timestamp":1610928162000},"page":"479-506","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":121,"title":["Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK)"],"prefix":"10.1007","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4526-8679","authenticated-orcid":false,"given":"A.","family":"Yilmaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Bauersachs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Bengel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"B\u00fcchel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Kindermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Klingel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Knebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Meder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Morbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Nagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Schulze-Bahr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"aus dem Siepen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Frey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,18]]},"reference":[{"issue":"2","key":"1799_CR1","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1159\/000495455","volume":"141","author":"I Vaxman","year":"2019","unstructured":"Vaxman I, Gertz M (2019) Recent advances in the diagnosis, risk stratification, and management of systemic light-chain amyloidosis. Acta Haematol 141(2):93\u2013106","journal-title":"Acta Haematol"},{"issue":"6","key":"1799_CR2","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s11897-019-00446-x","volume":"16","author":"S Ihne","year":"2019","unstructured":"Ihne S, Morbach C, Obici L, Palladini G, St\u00f6rk S (2019) Amyloidosis in heart failure. Curr Heart Fail Rep 16(6):285\u2013303","journal-title":"Curr Heart Fail Rep"},{"issue":"3","key":"1799_CR3","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1373\/clinchem.2008.117143","volume":"55","author":"G Palladini","year":"2009","unstructured":"Palladini G, Russo P, Bosoni T, Verga L, Sarais G, Lavatelli F, Nuvolone M, Obici L, Casarini S, Donadei S, Albertini R, Righetti G, Marini M, Graziani MS, Melzi D\u2019Eril GV, Moratti R, Merlini G (2009) Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. Clin Chem 55(3):499\u2013504. https:\/\/doi.org\/10.1373\/clinchem.2008.117143","journal-title":"Clin Chem"},{"issue":"16","key":"1799_CR4","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.2174\/0929867325666180104153338","volume":"26","author":"K Ablasser","year":"2019","unstructured":"Ablasser K, Verheyen N, Glantschnig T, Agnetti G, Rainer PP (2019) Unfolding cardiac amyloidosis\u2014from pathophysiology to cure. Curr Med Chem 26(16):2865\u20132878. https:\/\/doi.org\/10.2174\/0929867325666180104153338","journal-title":"Curr Med Chem"},{"issue":"Suppl 4","key":"1799_CR5","doi-asserted-by":"crossref","first-page":"16427","DOI":"10.1073\/pnas.202495199","volume":"99","author":"P Hammarstrom","year":"2002","unstructured":"Hammarstrom P, Jiang X, Hurshman AR, Powers ET, Kelly JW (2002) Sequence-dependent denaturation energetics: a major determinant in amyloid disease diversity. Proc Natl Acad Sci USA 99(Suppl 4):16427\u201316432","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"1799_CR6","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMra023144","volume":"349","author":"G Merlini","year":"2003","unstructured":"Merlini G, Bellotti V (2003) Molecular mechanisms of amyloidosis. N Engl J Med 349(6):583\u2013596","journal-title":"N Engl J Med"},{"issue":"4","key":"1799_CR7","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.bbrc.2011.04.133","volume":"410","author":"S Bourgault","year":"2011","unstructured":"Bourgault S, Choi S, Buxbaum JN, Kelly JW, Price JL, Reixach N (2011) Mechanisms of transthyretin cardiomyocyte toxicity inhibition by resveratrol analogs. Biochem Biophys Res Commun 410(4):707\u2013713","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"1799_CR8","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00428-001-0582-9","volume":"440","author":"C Rocken","year":"2002","unstructured":"Rocken C, Shakespeare A (2002) Pathology, diagnosis and pathogenesis of AA amyloidosis. Virchows Arch 440(2):111\u2013122","journal-title":"Virchows Arch"},{"issue":"6","key":"1799_CR9","doi-asserted-by":"publisher","first-page":"e005407","DOI":"10.1161\/CIRCHEARTFAILURE.118.005407","volume":"12","author":"LG Gilstrap","year":"2019","unstructured":"Gilstrap LG, Dominici F, Wang Y, E-Sady MS, Singh A, Di Carli MF, Falk RH, Dorbala S (2019) Epidemiology of cardiac amyloidosis-associated heart failure hospitalizations among fee-for-service Medicare beneficiaries in the United States. Circ Heart Fail 12(6):e005407. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.118.005407","journal-title":"Circ Heart Fail"},{"issue":"10","key":"1799_CR10","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1182\/bloodadvances.2018016402","volume":"2","author":"TP Quock","year":"2018","unstructured":"Quock TP, Yan T, Chang E, Guthrie S, Broder MS (2018) Epidemiology of AL amyloidosis: a realworld study using US claims data. Blood Adv 2(10):1046\u20131053","journal-title":"Blood Adv"},{"issue":"7","key":"1799_CR11","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1182\/blood.V79.7.1817.1817","volume":"79","author":"RA Kyle","year":"1992","unstructured":"Kyle RA, Linos A, Beard CM, Linke RP, Gertz MA, O\u2019Fallon WM, Kurland LT (1992) Incidence and natural history of primary systemic amyloidosis in Olmsted county, Minnesota, 1950 through 1989. Blood 79(7):1817\u20131822","journal-title":"Blood"},{"issue":"5","key":"1799_CR12","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1182\/blood-2011-07-370031","volume":"119","author":"S Madan","year":"2012","unstructured":"Madan S, Kumar SK, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Rajkumar SV, Hogan WJ, Leung N, Grogan M, Gertz MA (2012) High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement. Blood 119(5):1117\u20131122","journal-title":"Blood"},{"issue":"4","key":"1799_CR13","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/0002-9343(83)90443-6","volume":"75","author":"GG Cornwell III","year":"1983","unstructured":"Cornwell GG III, Murdoch WL, Kyle RA, Westermark P, Pitkanen P (1983) Frequency and distribution of senile cardiovascular amyloid A clinicopathologic correlation. Am J Med 75(4):618\u2013623","journal-title":"Am J Med"},{"issue":"38","key":"1799_CR14","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","volume":"36","author":"E Gonzalez-Lopez","year":"2015","unstructured":"Gonzalez-Lopez E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, Cobo-Marcos M, Robles C, Bornstein B, Salas C, Lara-Pezzi E, Alonso-Pulpon L, Garcia-Pavia P (2015) Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 36(38):2585\u20132594","journal-title":"Eur Heart J"},{"issue":"2","key":"1799_CR15","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jchf.2013.11.004","volume":"2","author":"SF Mohammed","year":"2014","unstructured":"Mohammed SF, Mirzoyev SA, Edwards WD, Dogan A, Grogan DR, Dunlay SM, Roger VL, Gertz MA, Dispenzieri A, Zeldenrust SR, Redfield MM (2014) Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Fail 2(2):113\u2013122","journal-title":"JACC Heart Fail"},{"issue":"4","key":"1799_CR16","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1080\/13506120802524676","volume":"15","author":"R Koivuniemi","year":"2008","unstructured":"Koivuniemi R, Paimela L, Suomalainen R, Tornroth T, Leirisalo-Repo M (2008) Amyloidosis is frequently undetected in patients with rheumatoid arthritis. Amyloid 15(4):262\u2013268","journal-title":"Amyloid"},{"issue":"2","key":"1799_CR17","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10741-015-9480-0","volume":"20","author":"C Rapezzi","year":"2015","unstructured":"Rapezzi C, Lorenzini M, Longhi S, Milandri A, Gagliardi C, Bartolomei I, Salvi F, Maurer MS (2015) Cardiac amyloidosis: the great pretender. Heart Fail Rev 20(2):117\u2013124","journal-title":"Heart Fail Rev"},{"key":"1799_CR18","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1750-1172-7-54","volume":"7","author":"E Desport","year":"2012","unstructured":"Desport E, Bridoux F, Sirac C, Delbes S, Bender S, Fernandez B, Quellard N, Lacombe C, Goujon JM, Lavergne D, Abraham J, Touchard G, Fermand JP, Jaccard A (2012) Al amyloidosis. Orphanet J Rare Dis 7:54","journal-title":"Orphanet J Rare Dis"},{"issue":"21","key":"1799_CR19","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1161\/CIRCULATIONAHA.107.697763","volume":"116","author":"D Feng","year":"2007","unstructured":"Feng D, Edwards WD, Oh JK, Chandrasekaran K, Grogan M, Martinez MW, Syed IS, Hughes DA, Lust JA, Jaffe AS, Gertz MA, Klarich KW (2007) Intracardiac thrombosis and embolism in patients with cardiac amyloidosis. Circulation 116(21):2420\u20132426","journal-title":"Circulation"},{"issue":"3","key":"1799_CR20","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3109\/13506129.2011.571319","volume":"18","author":"SB Tsai","year":"2011","unstructured":"Tsai SB, Seldin DC, Wu H, O\u2019Hara C, Ruberg FL, Sanchorawala V (2011) Myocardial infarction with \u201cclean coronaries\u201d caused by amyloid light-chain AL amyloidosis: a case report and literature review. Amyloid 18(3):160\u2013164","journal-title":"Amyloid"},{"issue":"4","key":"1799_CR21","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jchf.2014.03.009","volume":"2","author":"S Dorbala","year":"2014","unstructured":"Dorbala S, Vangala D, Bruyere J Jr, Quarta C, Kruger J, Padera R, Foster C, Hanley M, Di Carli MF, Falk R (2014) Coronary microvascular dysfunction is related to abnormalities in myocardial structure and function in cardiac amyloidosis. JACC Heart Fail 2(4):358\u2013367","journal-title":"JACC Heart Fail"},{"issue":"10","key":"1799_CR22","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1007\/s12325-015-0250-0","volume":"32","author":"I Lousada","year":"2015","unstructured":"Lousada I, Comenzo RL, Landau H, Guthrie S, Merlini G (2015) Light chain amyloidosis: patient experience survey from the Amyloidosis Research Consortium. Adv Ther 32(10):920\u2013928","journal-title":"Adv Ther"},{"issue":"9","key":"1799_CR23","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","volume":"30","author":"S Kumar","year":"2012","unstructured":"Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, Laumann K, Zeldenrust SR, Leung N, Dingli D, Greipp PR, Lust JA, Russell SJ, Kyle RA, Rajkumar SV, Gertz MA (2012) Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 30(9):989\u2013995","journal-title":"J Clin Oncol"},{"issue":"7","key":"1799_CR24","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.3324\/haematol.2018.205336","volume":"104","author":"T Dittrich","year":"2019","unstructured":"Dittrich T, Benner A, Kimmich C, Aus dem Siegen F, Veelken K, Kristen AV, Bochtler T, Katus HA, M\u00fcller-Tidow C, Hegenbart U, Sch\u00f6nland SO (2019) Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmia. Haematologica 104(7):1451\u20131459","journal-title":"Haematologica"},{"issue":"7","key":"1799_CR25","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/nrcardio.2010.67","volume":"7","author":"C Rapezzi","year":"2010","unstructured":"Rapezzi C, Quarta CC, Riva L, Longhi S, Gallelli I, Lorenzini M, Ciliberti P, Biagini E, Salvi F, Branzi A (2010) Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol 7(7):398\u2013408","journal-title":"Nat Rev Cardiol"},{"issue":"13","key":"1799_CR26","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1161\/CIRCULATIONAHA.108.843334","volume":"120","author":"C Rapezzi","year":"2009","unstructured":"Rapezzi C, Merlini G, Quarta CC, Riva L, Longhi S, Leone O, Salvi F, Ciliberti P, Pastorelli F, Biagini E, Coccolo F, Cooke RM, Bacchi-Reggiani L, Sangiorgi D, Ferlini A, Cavo M, Zamagni E, Fonte ML, Palladini G, Salinaro F, Musca F, Obici L, Branzi A, Perlini S (2009) Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation 120(13):1203\u20131212","journal-title":"Circulation"},{"issue":"14","key":"1799_CR27","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1161\/CIRCULATIONAHA.116.024438","volume":"135","author":"MS Maurer","year":"2017","unstructured":"Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C (2017) Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. Circulation 135(14):1357\u20131377","journal-title":"Circulation"},{"issue":"5","key":"1799_CR28","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1097\/HCO.0000000000000547","volume":"33","author":"J Nativi-Nicolau","year":"2018","unstructured":"Nativi-Nicolau J, Maurer MS (2018) Amyloidosis cardiomyopathy: update in the diagnosis and treatment of the most common types. Curr Opin Cardiol 33(5):571\u2013579","journal-title":"Curr Opin Cardiol"},{"key":"1799_CR29","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.amjcard.2020.05.021","volume":"128","author":"E Donnellan","year":"2020","unstructured":"Donnellan E, Wazni OM, Saliba WI, Hanna M, Kanj M, Patel DR, Wilner B, Kochar A, Jaber WA (2020) Prevalence, incidence, and impact on mortality of conduction system disease in transthyretin cardiac amyloidosis. Am J Cardiol 128:140\u2013146","journal-title":"Am J Cardiol"},{"issue":"22","key":"1799_CR30","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","volume":"73","author":"FL Ruberg","year":"2019","unstructured":"Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS (2019) Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol 73(22):2872\u20132891","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"1799_CR31","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12968-017-0415-x","volume":"19","author":"JL Cavalcante","year":"2017","unstructured":"Cavalcante JL, Rijal S, Abdelkarim I, Althouse AD, Sharbaugh MS, Fridman Y, Soman P, Forman DE, Schindler JT, Gleason TG, Lee JS, Schelbert EB (2017) Cardiac amyloidosis is prevalent in older patients with aortic stenosis and carries worse prognosis. J Cardiovasc Magn Reson 19(1):98","journal-title":"J Cardiovasc Magn Reson"},{"key":"1799_CR32","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jacc.2020.11.006","volume":"77","author":"C Nitsche","year":"2021","unstructured":"Nitsche C, Scully PR, Patel KP, Kammerlander A, Koschutnik M, Dona C, Wollenweber T, Ahmed N, Thornton GD, Kelion A, Sabharwal N, Newton JD, Ozkor M, Kennon S, Mullen M, Lloyd G, Fontana M, Hawkins P, Pugliese F, Menezes L, Moon JC, Mascherbauer J, Treibel TA (2021) Prevalence and outcomes of concomitant aortic stenosis and cardiac amyloidosis. J Am Coll Cardiol 77:128\u2013139. https:\/\/doi.org\/10.1016\/j.jacc.2020.11.006","journal-title":"J Am Coll Cardiol"},{"issue":"38","key":"1799_CR33","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","volume":"38","author":"A Castano","year":"2017","unstructured":"Castano A, Narotsky DL, Hamid N, Khalique OK, Morgenstern R, DeLuca A, Rubin J, Chiuzan C, Nazif T, Vahl T, George I, Kodali S, Leon MB, Hahn R, Bokhari S, Maurer MS (2017) Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J 38(38):2879\u20132887","journal-title":"Eur Heart J"},{"issue":"8","key":"1799_CR34","doi-asserted-by":"publisher","first-page":"e005066","DOI":"10.1161\/CIRCIMAGING.116.005066","volume":"9","author":"TA Treibel","year":"2016","unstructured":"Treibel TA, Fontana M, Gilbertson JA, Castelletti S, White SK, Scully PR, Roberts N, Hutt DF, Rowczenio DM, Whelan CJ, Ashworth MA, Gillmore JD, Hawkins PN, Moon JC (2016) Occult transthyretin cardiac amyloid in severe calcific aortic stenosis: prevalence and prognosis in patients undergoing surgical aortic valve replacement. Circ Cardiovasc Imaging 9(8):e005066. https:\/\/doi.org\/10.1161\/CIRCIMAGING.116.005066","journal-title":"Circ Cardiovasc Imaging"},{"issue":"2","key":"1799_CR35","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","volume":"68","author":"MS Maurer","year":"2016","unstructured":"Maurer MS, Hanna M, Grogan M, Dispenzieri A, Witteles R, Drachman B, Judge DP, Lenihan DJ, Gottlieb SS, Shah SJ, Steidley DE, Ventura H, Murali S, Silver MA, Jacoby D, Fedson S, Hummel SL, Kristen AV, Damy T, Plante-Bordeneuve V, Coelho T, Mundayat R, Suhr OB, Waddington CM, Rapezzi C (2016) Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol 68(2):161\u2013172","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"1799_CR36","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ahj.2012.04.015","volume":"164","author":"FL Ruberg","year":"2012","unstructured":"Ruberg FL, Maurer MS, Judge DP, Zeldenrust S, Skinner M, Kim AY, Falk RH, Cheung KN, Patel AR, Pano A, Packman J, Grogan DR (2012) Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS). Am Heart J 164(2):222\u2013228","journal-title":"Am Heart J"},{"issue":"10","key":"1799_CR37","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","volume":"68","author":"M Grogan","year":"2016","unstructured":"Grogan M, Scott CG, Kyle RA, Zeldenrust SR, Gertz MA, Lin G, Klarich KW, Miller WL, Maleszewski JJ, Dispenzieri A (2016) Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol 68(10):1014\u20131020","journal-title":"J Am Coll Cardiol"},{"issue":"30","key":"1799_CR38","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","volume":"39","author":"JD Gillmore","year":"2018","unstructured":"Gillmore JD, Damy T, Fontana M, Hutchinson M, Lachman HJ, Martinez-Naharro A, Quarta CC, Rezk T, Whelan CJ, Gonzalez-Lopez E, Lane T, Gilberson JA, Rowczenio D, Petrie A, Hawkins PN (2018) A new staging system for cardiac transthyretin amyloidosis. Eur Heart J 39(30):2799\u20132806","journal-title":"Eur Heart J"},{"issue":"3","key":"1799_CR39","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1161\/CIRCULATIONAHA.115.018852","volume":"133","author":"LH Connors","year":"2016","unstructured":"Connors LH, Sam F, Skinner M, Salinaro F, Sun F, Ruberg FL, Berk JL, Seldin DC (2016) Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: a prospective, observational cohort study. Circulation 133(3):282\u2013290","journal-title":"Circulation"},{"issue":"11","key":"1799_CR40","first-page":"376","volume":"29","author":"S Janssen","year":"1986","unstructured":"Janssen S, van Rijswijk MH, Meijer S, Ruinen L, Van der Hem GK (1986) Systemic amyloidosis: a clinical survey of 144 cases. Neth J Med 29(11):376\u2013385","journal-title":"Neth J Med"},{"issue":"23","key":"1799_CR41","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1056\/NEJMoa070265","volume":"356","author":"HJ Lachmann","year":"2007","unstructured":"Lachmann HJ, Goodman HJ, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD, Hawkins PN (2007) Natural history and outcome in systemic AA amyloidosis. N Engl J Med 356(23):2361\u20132371","journal-title":"N Engl J Med"},{"issue":"3","key":"1799_CR42","first-page":"343","volume":"21","author":"F Tanaka","year":"2003","unstructured":"Tanaka F, Migita K, Honda S, Fukuda T, Mine M, Nakamura T, Yamasaki S, Ida H, Kawakami A, Origuchi T, Eguchi K (2003) Clinical outcome and survival of secondary (AA) amyloidosis. Clin Exp Rheumatol 21(3):343\u2013346","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"1799_CR43","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1093\/ndt\/gfm684","volume":"23","author":"F Bergesio","year":"2008","unstructured":"Bergesio F, Ciciani AM, Manganaro M, Palladini G, Santostefano M, Brugnano R, Di Palma AM, Gallo M, Rosati A, Tosi PL, Salvadori M (2008) Renal involvement in systemic amyloidosis: an Italian collaborative study on survival and renal outcome. Nephrol Dial Transplant 23(3):941\u2013951","journal-title":"Nephrol Dial Transplant"},{"issue":"30","key":"1799_CR44","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","volume":"39","author":"JD Gillmore","year":"2018","unstructured":"Gillmore JD, Damy T, Fontana M, Hutchinson M, Lachmann HJ, Martinez-Naharro A, Quarta CC, Rezk T, Whelan CJ, Gonzalez-Lopez E, Lane T, Gilbertson JA, Rowczenio D, Petrie A, Hawkins PN (2018) A new staging system for cardiac transthyretin amyloidosis. Eur Heart J 39(30):2799\u20132806","journal-title":"Eur Heart J"},{"issue":"2","key":"1799_CR45","doi-asserted-by":"crossref","first-page":"e004000","DOI":"10.1161\/CIRCHEARTFAILURE.117.004000","volume":"11","author":"JLS Hanson","year":"2018","unstructured":"Hanson JLS, Arvanitis M, Koch CM, Berk JL, Ruberg FL, Prokaeva T, Connors LH (2018) Use of serum transthyretin as a prognostic indicator and predictor of outcome in cardiac amyloid disease associated with wild-type transthyretin. Circ Heart Fail 11(2):e004000","journal-title":"Circ Heart Fail"},{"issue":"9","key":"1799_CR46","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1002\/ajh.25149","volume":"93","author":"MA Gertz","year":"2018","unstructured":"Gertz MA (2018) Immunoglobulin light chain amyloidosis: 2018 update on diagnosis, prognosis, and treatment. Am J Hematol 93(9):1169\u20131180","journal-title":"Am J Hematol"},{"key":"1799_CR47","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.ijcard.2016.04.030","volume":"214","author":"BW Sperry","year":"2016","unstructured":"Sperry BW, Vranian MN, Hachamovitch R, Joshi H, McCarthy M, Ikram A, Hanna M (2016) Are classic predictors of voltage valid in cardiac amyloidosis? A contemporary analysis of electrocardiographic findings. Int J Cardiol 214:477\u2013481","journal-title":"Int J Cardiol"},{"issue":"4","key":"1799_CR48","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.amjcard.2011.09.052","volume":"109","author":"M Namdar","year":"2012","unstructured":"Namdar M, Steffel J, Jetzer S, Schmied C, Hurlimann D, Camici GG, Bayrak F, Ricciardi D, Rao JY, de Asmundis C, Chierchia GB, Sarkozy A, Luscher TF, Jenni R, Duru F, Brugada P (2012) Value of electrocardiogram in the differentiation of hypertensive heart disease, hypertrophic cardiomyopathy, aortic stenosis, amyloidosis, and Fabry disease. Am J Cardiol 109(4):587\u2013593","journal-title":"Am J Cardiol"},{"issue":"16","key":"1799_CR49","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1093\/eurheartj\/ehz057","volume":"40","author":"MP van den Berg","year":"2019","unstructured":"van den Berg MP, Mulder BA, Klaassen SHC, Maass AH, Van Veldhuisen DJ, van der Meer P, Nienhuis HLA, Hazenberg BPC, Rienstra M (2019) Heart failure with preserved ejection fraction, atrial fibrillation, and the role of senile amyloidosis. Eur Heart J 40(16):1287\u20131293. https:\/\/doi.org\/10.1093\/eurheartj\/ehz057","journal-title":"Eur Heart J"},{"issue":"21","key":"1799_CR50","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/eurheartj\/ehy037","volume":"39","author":"M Brignole","year":"2018","unstructured":"Brignole M, Moya A, de Lange FJ, Deharo JC, Elliott PM, Fanciulli A, Fedorowski A, Furlan R, Kenny RA, Martin A, Probst V, Reed MJ, Rice CP, Sutton R, Ungar A, van Dijk JG (2018) 2018 ESC Guidelines for the diagnosis and management of syncope. Eur Heart J 39(21):1883\u20131948","journal-title":"Eur Heart J"},{"issue":"1","key":"1799_CR51","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0167-5273(92)90115-J","volume":"36","author":"JF Navarro","year":"1992","unstructured":"Navarro JF, Rivera M, Ortuno J (1992) Cardiac tamponade as presentation of systemic amyloidosis. Int J Cardiol 36(1):107\u2013108","journal-title":"Int J Cardiol"},{"issue":"3","key":"1799_CR52","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/ehjci\/jev014","volume":"16","author":"RM Lang","year":"2015","unstructured":"Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU (2015) Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 16(3):233\u2013270","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"27","key":"1799_CR53","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37(27):2129\u20132200","journal-title":"Eur Heart J"},{"issue":"19","key":"1799_CR54","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1136\/heartjnl-2012-302353","volume":"98","author":"D Phelan","year":"2012","unstructured":"Phelan D, Collier P, Thavendiranathan P, Popovic ZB, Hanna M, Plana JC, Marwick TH, Thomas JD (2012) Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart 98(19):1442\u20131448","journal-title":"Heart"},{"issue":"2","key":"1799_CR55","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jcmg.2015.05.014","volume":"9","author":"J Ternacle","year":"2016","unstructured":"Ternacle J, Bodez D, Guellich A, Audureau E, Rappeneau S, Lim P, Radu C, Guendouz S, Couetil JP, Benhaiem N, Hittinger L, Dubois-Rande JL, Plante-Bordeneuve V, Mohty D, Deux JF, Damy T (2016) Causes and consequences of longitudinal LV dysfunction assessed by 2D strain echocardiography in cardiac amyloidosis. JACC Cardiovasc Imaging 9(2):126\u2013138","journal-title":"JACC Cardiovasc Imaging"},{"issue":"3","key":"1799_CR56","doi-asserted-by":"crossref","first-page":"e005588","DOI":"10.1161\/CIRCIMAGING.116.005588","volume":"10","author":"ED Pagourelias","year":"2017","unstructured":"Pagourelias ED, Mirea O, Duchenne J, Van CJ, Delforge M, Bogaert J, Kuznetsova T, Voigt JU (2017) Echo parameters for differential diagnosis in cardiac amyloidosis: a head-to-head comparison of deformation and nondeformation parameters. Circ Cardiovasc Imaging 10(3):e005588","journal-title":"Circ Cardiovasc Imaging"},{"issue":"11","key":"1799_CR57","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/ehjci\/jex182","volume":"18","author":"R Senior","year":"2017","unstructured":"Senior R, Becher H, Monaghan M, Agati L, Zamorano J, Vanoverschelde JL, Nihoyannopoulos P, Edvardsen T, Lancellotti P (2017) Clinical practice of contrast echocardiography: recommendation by the European Association of Cardiovascular Imaging (EACVI) 2017. Eur Heart J Cardiovasc Imaging 18(11):1205\u20131205af","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"12","key":"1799_CR58","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.jcmg.2015.11.001","volume":"8","author":"P Claus","year":"2015","unstructured":"Claus P, Omar AMS, Pedrizzetti G, Sengupta PP, Nagel E (2015) Tissue tracking technology for assessing cardiac mechanics: principles, normal values, and clinical applications. JACC Cardiovasc Imaging 8(12):1444\u20131460","journal-title":"JACC Cardiovasc Imaging"},{"issue":"1","key":"1799_CR59","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1532-429X-10-54","volume":"10","author":"AM Maceira","year":"2008","unstructured":"Maceira AM, Prasad SK, Hawkins PN, Roughton M, Pennell DJ (2008) Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis. J Cardiovasc Magn Reson 10(1):54","journal-title":"J Cardiovasc Magn Reson"},{"issue":"2","key":"1799_CR60","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jcmg.2009.09.023","volume":"3","author":"IS Syed","year":"2010","unstructured":"Syed IS, Glockner JF, Feng D, Araoz PA, Martinez MW, Edwards WD, Gertz MA, Dispenzieri A, Oh JK, Bellavia D, Tajik AJ, Grogan M (2010) Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging 3(2):155\u2013164","journal-title":"JACC Cardiovasc Imaging"},{"issue":"10","key":"1799_CR61","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.jacc.2007.10.049","volume":"51","author":"H Vogelsberg","year":"2008","unstructured":"Vogelsberg H, Mahrholdt H, Deluigi CC, Yilmaz A, Kispert EM, Greulich S, Klingel K, Kandolf R, Sechtem U (2008) Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy. J Am Coll Cardiol 51(10):1022\u20131030","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"1799_CR62","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jcmg.2013.09.019","volume":"7","author":"JA White","year":"2014","unstructured":"White JA, Kim HW, Shah D, Fine N, Kim KY, Wendell DC, Al-Jaroudi W, Parker M, Patel M, Gwadry-Sridhar F, Judd RM, Kim RJ (2014) CMR imaging with rapid visual T1 assessment predicts mortality in patients suspected of cardiac amyloidosis. JACC Cardiovasc Imaging 7(2):143\u2013156","journal-title":"JACC Cardiovasc Imaging"},{"issue":"6","key":"1799_CR63","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jcmg.2015.10.027","volume":"9","author":"SJ Boynton","year":"2016","unstructured":"Boynton SJ, Geske JB, Dispenzieri A, Syed IS, Hanson TJ, Grogan M, Araoz PA (2016) LGE provides incremental prognostic information over serum biomarkers in AL cardiac amyloidosis. JACC Cardiovasc Imaging 9(6):680\u2013686","journal-title":"JACC Cardiovasc Imaging"},{"issue":"16","key":"1799_CR64","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1161\/CIRCULATIONAHA.115.016567","volume":"132","author":"M Fontana","year":"2015","unstructured":"Fontana M, Pica S, Reant P, Abdel-Gadir A, Treibel TA, Banypersad SM, Maestrini V, Barcella W, Rosmini S, Bulluck H, Sayed RH, Patel K, Mamhood S, Bucciarelli-Ducci C, Whelan CJ, Herrey AS, Lachmann HJ, Wechalekar AD, Manisty CH, Schelbert EB, Kellman P, Gillmore JD, Hawkins PN, Moon JC (2015) Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 132(16):1570\u20131579","journal-title":"Circulation"},{"issue":"2","key":"1799_CR65","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1161\/CIRCRESAHA.116.307974","volume":"119","author":"VO Puntmann","year":"2016","unstructured":"Puntmann VO, Peker E, Chandrashekhar Y, Nagel E (2016) T1 mapping in characterizing myocardial disease: a comprehensive review. Circ Res 119(2):277\u2013299","journal-title":"Circ Res"},{"issue":"2","key":"1799_CR66","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jcmg.2013.10.008","volume":"7","author":"M Fontana","year":"2014","unstructured":"Fontana M, Banypersad SM, Treibel TA, Maestrini V, Sado DM, White SK, Pica S, Castelletti S, Piechnik SK, Robson MD, Gilbertson JA, Rowczenio D, Hutt DF, Lachmann HJ, Wechalekar AD, Whelan CJ, Gillmore JD, Hawkins PN, Moon JC (2014) Native T1 mapping in transthyretin amyloidosis. JACC Cardiovasc Imaging 7(2):157\u2013165","journal-title":"JACC Cardiovasc Imaging"},{"issue":"12","key":"1799_CR67","doi-asserted-by":"crossref","first-page":"e003285","DOI":"10.1161\/CIRCIMAGING.115.003285","volume":"8","author":"R Hinojar","year":"2015","unstructured":"Hinojar R, Varma N, Child N, Goodman B, Jabbour A, Yu CY, Gebker R, Doltra A, Kelle S, Khan S, Rogers T, Arroyo UE, Cummins C, Carr-White G, Nagel E, Puntmann VO (2015) T1 mapping in discrimination of hypertrophic phenotypes: hypertensive heart disease and hypertrophic cardiomyopathy: findings from the International T1 Multicenter Cardiovascular Magnetic Resonance Study. Circ Cardiovasc Imaging 8(12):e003285","journal-title":"Circ Cardiovasc Imaging"},{"issue":"4","key":"1799_CR68","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.jcmg.2012.11.013","volume":"6","author":"TD Karamitsos","year":"2013","unstructured":"Karamitsos TD, Piechnik SK, Banypersad SM, Fontana M, Ntusi NB, Ferreira VM, Whelan CJ, Myerson SG, Robson MD, Hawkins PN, Neubauer S, Moon JC (2013) Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging 6(4):488\u2013497","journal-title":"JACC Cardiovasc Imaging"},{"issue":"1","key":"1799_CR69","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12968-017-0389-8","volume":"19","author":"DR Messroghli","year":"2017","unstructured":"Messroghli DR, Moon JC, Ferreira VM, Grosse-Wortmann L, He T, Kellman P, Mascherbauer J, Nezafat R, Salerno M, Schelbert EB, Taylor AJ, Thompson R, Ugander M, van Heeswijk RB, Friedrich MG (2017) Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: a consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI). J Cardiovasc Magn Reson 19(1):75","journal-title":"J Cardiovasc Magn Reson"},{"issue":"5","key":"1799_CR70","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jcmg.2018.02.006","volume":"12","author":"A Martinez-Naharro","year":"2018","unstructured":"Martinez-Naharro A, Kotecha T, Norrington K, Boldrini M, Rezk T, Quarta C, Treibel TA, Whelan CJ, Knight DS, Kellman P, Ruberg FL, Gillmore JD, Moon JC, Hawkins PN, Fontana M (2018) Native T1 and extracellular volume in transthyretin amyloidosis. JACC Cardiovasc Imaging 12(5):810\u2013819","journal-title":"JACC Cardiovasc Imaging"},{"issue":"5","key":"1799_CR71","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.jcmg.2018.03.029","volume":"12","author":"A Yilmaz","year":"2018","unstructured":"Yilmaz A (2018) The, \u201cnative T1 versus extracellular volume fraction paradox\u201d in cardiac amyloidosis: answer to the million-dollar question? JACC Cardiovasc Imaging 12(5):820\u2013822","journal-title":"JACC Cardiovasc Imaging"},{"issue":"1","key":"1799_CR72","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/ehf2.12382","volume":"6","author":"Y Shintani","year":"2019","unstructured":"Shintani Y, Okada A, Morita Y, Hamatani Y, Amano M, Takahama H, Amaki M, Hasegawa T, Ohta-Ogo K, Kanzaki H, Ishibasi-Ueda H, Yasuda S, Shimazaki C, Yoshinaga T, Yazaki M, Sekijima Y, Izumi C (2019) Monitoring treatment response to tafamidis by serial native T1 and extracellular volume in transthyretin amyloid cardiomyopathy. ESC Heart Fail 6(1):232\u2013236","journal-title":"ESC Heart Fail"},{"issue":"7","key":"1799_CR73","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s00392-020-01611-2","volume":"109","author":"A Florian","year":"2020","unstructured":"Florian A, Bietenbeck M, Chatzantonis G, H\u00fcsing-Kabar A, Schmidt H, Yilmaz A (2020) Regression of cardiac amyloid load documented by cardiovascular magnetic resonance in a patient with hereditary amyloidosis. Clin Res Cardiol 109(7):949\u2013956","journal-title":"Clin Res Cardiol"},{"issue":"5","key":"1799_CR74","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/0002-8703(82)90394-5","volume":"103","author":"P Nicod","year":"1982","unstructured":"Nicod P, Lewis SE, Corbett JC, Buja LM, Henderson G, Raskin P, Rude RE, Willerson JT (1982) Increased incidence and clinical correlation of persistently abnormal technetium pyrophosphate myocardial scintigrams following acute myocardial infarction in patients with diabetes mellitus. Am Heart J 103(5):822\u2013829","journal-title":"Am Heart J"},{"issue":"4 Pt 1","key":"1799_CR75","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/0002-8703(82)90331-3","volume":"103","author":"TA Wizenberg","year":"1982","unstructured":"Wizenberg TA, Muz J, Sohn YH, Samlowski W, Weissler AM (1982) Value of positive myocardial technetium-99m-pyrophosphate scintigraphy in the noninvasive diagnosis of cardiac amyloidosis. Am Heart J 103(4 Pt 1):468\u2013473","journal-title":"Am Heart J"},{"issue":"2","key":"1799_CR76","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1161\/CIRCIMAGING.112.000132","volume":"6","author":"S Bokhari","year":"2013","unstructured":"Bokhari S, Castano A, Pozniakoff T, Deslisle S, Latif F, Maurer MS (2013) (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging 6(2):195\u2013201","journal-title":"Circ Cardiovasc Imaging"},{"issue":"1","key":"1799_CR77","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3109\/13506129.2013.871250","volume":"21","author":"AW Glaudemans","year":"2014","unstructured":"Glaudemans AW, van Rheenen RW, van den Berg MP, Noordzij W, Koole M, Blokzijl H, Dierckx RA, Slart RH, Hazenberg BP (2014) Bone scintigraphy with (99m)technetium-hydroxymethylene diphosphonate allows early diagnosis of cardiac involvement in patients with transthyretin-derived systemic amyloidosis. Amyloid 21(1):35\u201344","journal-title":"Amyloid"},{"issue":"6","key":"1799_CR78","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2005.05.073","volume":"46","author":"E Perugini","year":"2005","unstructured":"Perugini E, Guidalotti PL, Salvi F, Cooke RM, Pettinato C, Riva L, Leone O, Farsad M, Ciliberti P, Bacchi-Reggiani L, Fallani F, Branzi A, Rapezzi C (2005) Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 46(6):1076\u20131084","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"1799_CR79","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s12350-018-1307-7","volume":"27","author":"AJ Einstein","year":"2020","unstructured":"Einstein AJ, Shuryak I, Casta\u00f1o A, Mintz A, Maurer MS, Bokhari S (2020) Estimating cancer risk from 99m Tc pyrophosphate imaging for transthyretin cardiac amyloidosis. J Nucl Cardiol 27(1):215\u2013224","journal-title":"J Nucl Cardiol"},{"issue":"1","key":"1799_CR80","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s12350-018-01552-4","volume":"26","author":"V Singh","year":"2019","unstructured":"Singh V, Falk R, Di Carli MF, Kijewski M, Rapezzi C, Dorbala S (2019) State-of-the-art radionuclide imaging in cardiac transthyretin amyloidosis. J Nucl Cardiol 26(1):158\u2013173","journal-title":"J Nucl Cardiol"},{"issue":"2","key":"1799_CR81","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1161\/CIRCIMAGING.112.000132","volume":"6","author":"S Bokhari","year":"2013","unstructured":"Bokhari S, Casta\u00f1o A, Pozniakoff T, Deslisle S, Latif F, Maurer MS (2013) (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging 6(2):195\u2013201","journal-title":"Circ Cardiovasc Imaging"},{"issue":"6","key":"1799_CR82","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jcmg.2011.03.016","volume":"4","author":"C Rapezzi","year":"2011","unstructured":"Rapezzi C, Quarta CC, Guidalotti PL, Pettinato C, Fanti S, Leone O, Ferlini A, Longhi S, Lorenzini M, Bacchi Reggiani L, Gagliardi C, Gallo P, Villani C, Salvi F (2011) Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. JACC Cardiovasc imaging 4(6):659\u2013670","journal-title":"JACC Cardiovasc imaging"},{"issue":"3","key":"1799_CR83","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s00259-010-1642-7","volume":"38","author":"C Rapezzi","year":"2011","unstructured":"Rapezzi C, Quarta CC, Guidalotti PL, Longhi S, Pettinato C, Leone O, Ferlini A, Salvi F, Gallo P, Gagliardi C, Branzi A (2011) Usefulness and limitations of 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy. Eur J Nucl Med Mol Imaging 38(3):470\u2013478","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"1799_CR84","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3109\/13506129.2015.1072089","volume":"22","author":"A Galat","year":"2015","unstructured":"Galat A, Rosso J, Guellich A, Van Der Gucht A, Rappeneau S, Bodez D, Guendouz S, Tissot C-M, Hittinger L, Dubois-Rand\u00e9 J-L, Plante-Bordeneuve V, Itti E, Meignan M, Damy T (2015) Usefulness of (99m)Tc-HMDP scintigraphy for the etiologic diagnosis and prognosis of cardiac amyloidosis. Amyloid 22(4):210\u2013220","journal-title":"Amyloid"},{"issue":"11","key":"1799_CR85","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1007\/s00259-018-4013-4","volume":"45","author":"G Treglia","year":"2018","unstructured":"Treglia G, Glaudemans AWJM, Bertagna F, Hazenberg BPC, Erba PA, Giubbini R, Ceriani L, Prior JO, Giovanella L, Slart RHJA (2018) Diagnostic accuracy of bone scintigraphy in the assessment of cardiac transthyretin-related amyloidosis: a bivariate meta-analysis. Eur J Nucl Med Mol Imaging 45(11):1945\u20131955","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"24","key":"1799_CR86","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","volume":"133","author":"JA Gillmore","year":"2016","unstructured":"Gillmore JA, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, Wechalekar AD, Berk JL, Quarta C, Grogan M, Lachmann HJ, Bokhari S, Castano A, Dorbala S, Johnson GB, Glaudemans AWJM, Rezk T, Fontana M, Palladini G, Milani P, Guidalotti PL, Flatman K, Lane T, Vonberg FW, Whelan CJ, Moon JC, Ruberg FL, Miller EJ, Hutt DF, Hazenberg BP, Rapezzi C, Hawkins PN (2016) Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 133(24):2404\u20132412","journal-title":"Circulation"},{"issue":"8","key":"1799_CR87","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1093\/ehjci\/jeaa063","volume":"21","author":"R Jurcut","year":"2020","unstructured":"Jurcut R, Onciul S, Adam R, Stan C, Coriu D, Rapezzi C, Popescu BA (2020) Multimodality imaging in cardiac amyloidosis: a primer for cardiologists. Eur Heart J Cardiovasc Imaging 21(8):833\u2013844","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"11","key":"1799_CR88","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.cardfail.2019.08.001","volume":"25","author":"S Dorbala","year":"2019","unstructured":"Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, Fontana M, Gheysens O, Gillmore JD, Glaudemans AWJM, Hanna MA, Hazenberg BPC, Kristen AV, Kwong RY, Maurer MS, Merlkini G, Miller EJ, Moon JC, Murthy VL, Quarta CC, Rapezzi C, Ruberg FL, Shah SJ, Slart RHJA, Verberne HJ, Bourque JM (2019) ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI Expert Consensus Recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging. J Card Fail 25(11):e1\u2013e39. https:\/\/doi.org\/10.1016\/j.cardfail.2019.08.001","journal-title":"J Card Fail"},{"issue":"1","key":"1799_CR89","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","volume":"142","author":"MM Kittleson","year":"2020","unstructured":"Kittleson MM, Maurer MS, Ambardekar AV, Bullock-Palmer RP, Chang PP, Eisen HJ, Nair AP, Nativi-Nicolau J, Ruberg FL (2020) American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology. Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association. Circulation 142(1):e7\u2013e22. https:\/\/doi.org\/10.1161\/CIR.0000000000000792","journal-title":"Circulation"},{"issue":"25","key":"1799_CR90","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1093\/eurheartj\/ehaa091","volume":"41","author":"ME Layoun","year":"2020","unstructured":"Layoun ME, Desmarais J, Heitner SB, Masri A (2020) Hot hearts on bone scintigraphy are not all amyloidosis: hydroxychloroquine-induced restrictive cardiomyopathy. Eur Heart J 41(25):2414","journal-title":"Eur Heart J"},{"issue":"1","key":"1799_CR91","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3109\/03009734.2015.1122687","volume":"121","author":"B Pilebro","year":"2016","unstructured":"Pilebro B, Suhr OB, N\u00e4slund U, Westermark P, Lindqvist P, Sundstr\u00f6m T (2016) (99m)Tc-DPD uptake reflects amyloid fibril composition in hereditary transthyretin amyloidosis. Ups J Med Sci 121(1):17\u201324","journal-title":"Ups J Med Sci"},{"issue":"3","key":"1799_CR92","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/13506129.2018.1520087","volume":"25","author":"JC Ross","year":"2018","unstructured":"Ross JC, Hutt DF, Burniston M, Page J, Steeden JA, Gillmore JD, Wechalekar AD, Hawkins PN, Fontana M (2018) Quantitation of (99m)Tc-DPD uptake in patients with transthyretin-related cardiac amyloidosis. Amyloid 25(3):203\u2013210","journal-title":"Amyloid"},{"issue":"1","key":"1799_CR93","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s12350-018-1365-x","volume":"27","author":"YJ Kim","year":"2018","unstructured":"Kim YJ, Ha S, Kim YI (2018) Cardiac amyloidosis imaging with amyloid positron emission tomography: A systematic review and meta-analysis. J Nucl Cardiol 27(1):123\u2013132","journal-title":"J Nucl Cardiol"},{"issue":"1","key":"1799_CR94","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13550-018-0425-1","volume":"8","author":"L Baratto","year":"2018","unstructured":"Baratto L, Park SY, Hatami N, Gulaka P, Vasanawala S, Yohannan TK, Herfkens R, Witteles R, Iagaru A (2018) (18)F-florbetaben whole-body PET\/MRI for evaluation of systemic amyloid deposition. EJNMMI Res 8(1):66","journal-title":"EJNMMI Res"},{"issue":"9","key":"1799_CR95","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1007\/s00259-014-2787-6","volume":"41","author":"S Dorbala","year":"2014","unstructured":"Dorbala S, Vangala D, Semer J, Strader C, Bruyere JR Jr, Di Carli MF, Moore SC, Falk RH (2014) Imaging cardiac amyloidosis: a pilot study using (1)(8)F-florbetapir positron emission tomography. Eur J Nucl Med Mol Imaging 41(9):1652\u20131662","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"1799_CR96","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jcmg.2014.09.018","volume":"8","author":"SP Lee","year":"2015","unstructured":"Lee SP, Lee ES, Choi H, Im HJ, Koh Y, Lee MH, Kwon JH, Paeng JC, Kim HK, Cheon GJ, Kim YJ, Kim I, Yoon SS, Seo JW, Sohn DW (2015) 11C-Pittsburgh B PET imaging in cardiac amyloidosis. JACC Cardiovasc Imaging 8(1):50\u201359","journal-title":"JACC Cardiovasc Imaging"},{"issue":"4","key":"1799_CR97","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1053\/j.semnuclmed.2011.03.001","volume":"41","author":"J Lister-James","year":"2011","unstructured":"Lister-James J, Pontecorvo MJ, Clark C, Joshi AD, Mintun MA, Zhang W, Lim N, Zhuang Z, Golding G, Choi SR, Benedum TE, Kennedy P, Hefti F, Carpenter AP, Kung HF, Skovronsky DM (2011) Florbetapir f-18: a histopathologically validated Beta-amyloid positron emission tomography imaging agent. Semin Nucl Med 41(4):300\u2013304","journal-title":"Semin Nucl Med"},{"issue":"2","key":"1799_CR98","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2967\/jnumed.108.055756","volume":"50","author":"GJ O\u2019Keefe","year":"2009","unstructured":"O\u2019Keefe GJ, Saunder TH, Ng S, Ackerman U, Tochon-Danguy HJ, Chan JG, Gong S, Dyrks T, Lindemann S, Holl G, Dinkelborg L, Villemagne V, Rowe CC (2009) Radiation dosimetry of beta-amyloid tracers 11C-PiB and 18F-BAY94-9172. J Nucl Med 50(2):309\u2013315","journal-title":"J Nucl Med"},{"issue":"4","key":"1799_CR99","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jacc.2019.11.037","volume":"75","author":"S-P Lee","year":"2020","unstructured":"Lee S-P, Suh H-Y, Park S, Oh S, Kwak S-G, Kim H-M, Koh Y, Park J-B, Kim H-K, Cho H-J, Kim Y-J, Kim I, Yoon S-S, Seo J-W, Paeng J-C, Sohn D-W (2020) Pittsburgh B compound positron emission tomography in patients with AL cardiac amyloidosis. J Am Coll Cardiol 75(4):380\u2013390","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"1799_CR100","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1161\/CIRCULATIONAHA.107.743427","volume":"118","author":"M Holzmann","year":"2008","unstructured":"Holzmann M, Nicko A, Kuhl U, Noutsias M, Poller W, Hoffmann W, Morguet A, Witzenbichler B, Tschope C, Schultheiss HP, Pauschinger M (2008) Complication rate of right ventricular endomyocardial biopsy via the femoral approach: a retrospective and prospective study analyzing 3048 diagnostic procedures over an 11-year period. Circulation 118(17):1722\u20131728","journal-title":"Circulation"},{"issue":"9","key":"1799_CR101","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1161\/CIRCULATIONAHA.109.924167","volume":"122","author":"A Yilmaz","year":"2010","unstructured":"Yilmaz A, Kindermann I, Kindermann M, Mahfoud F, Ukena C, Athanasiadis A, Hill S, Mahrholdt H, Voehringer M, Schieber M, Klingel K, Kandolf R, Bohm M, Sechtem U (2010) Comparative evaluation of left and right ventricular endomyocardial biopsy: differences in complication rate and diagnostic performance. Circulation 122(9):900\u2013909","journal-title":"Circulation"},{"issue":"7","key":"1799_CR102","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.pathol.2017.08.004","volume":"49","author":"T Khan","year":"2017","unstructured":"Khan T, Selvakumar D, Trivedi S, Rao K, Harapoz M, Thiagalingam A, Denniss AR, Varikatt W (2017) The value of endomyocardial biopsy in diagnosis and guiding therapy. Pathology 49(7):750\u2013756","journal-title":"Pathology"},{"issue":"19","key":"1799_CR103","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1161\/CIRCULATIONAHA.117.030834","volume":"137","author":"N Frey","year":"2018","unstructured":"Frey N, Meder B, Katus HA (2018) Left ventricular biopsy in the diagnosis of myocardial diseases. Circulation 137(19):993\u2013995","journal-title":"Circulation"},{"issue":"1","key":"1799_CR104","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jacc.2016.04.035","volume":"68","author":"AV Kristen","year":"2016","unstructured":"Kristen AV, Brokbals E, dem Aus SF, Bauer R, Hein S, Aurich M, Riffel J, Behrens HM, Kruger S, Schirmacher P, Katus HA, Rocken C (2016) Cardiac amyloid load: a prognostic and predictive biomarker in patients with light-chain amyloidosis. J Am Coll Cardiol 68(1):13\u201324","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"1799_CR105","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/echo.14245","volume":"36","author":"P Mehta","year":"2019","unstructured":"Mehta P, Chapel DB, Goyal N, Yu DB, Mor-Avi V, Narang A, Addetia K, Sarswat N, Lang RM, Husain AN, Patel AR (2019) A histopathologic schema to quantify the burden of cardiac amyloidosis: relationship with survival and echocardiographic parameters. Echocardiography 36(2):285\u2013291","journal-title":"Echocardiography"},{"issue":"10","key":"1799_CR106","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/j.amjcard.2014.02.030","volume":"113","author":"NM Fine","year":"2014","unstructured":"Fine NM, Arruda-Olson AM, Dispenzieri A, Zeldenrust SR, Gertz MA, Kyle RA, Swiecicki PL, Scott CG, Grogan M (2014) Yield of noncardiac biopsy for the diagnosis of transthyretin cardiac amyloidosis. Am J Cardiol 113(10):1723\u20131727","journal-title":"Am J Cardiol"},{"key":"1799_CR107","doi-asserted-by":"publisher","unstructured":"Cendrowska U, Silva PJ, Ait-Bouziad N, M\u00fcller M, Guven ZP, Vieweg S, Chiki A, Radamaker L, Kumar ST, F\u00e4ndrich M, Tavanti F, Menziani MC, Alexander-Katz A, Stellacci F, Lashuel HA (2020) Unraveling the complexity of amyloid polymorphism using gold nanoparticles and cryo-EM. Proc Natl Acad Sci USA 117(12):6866\u20136874. https:\/\/doi.org\/10.1073\/pnas.1916176117.","DOI":"10.1073\/pnas.1916176117"},{"issue":"13","key":"1799_CR108","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMoa054494","volume":"354","author":"RA Kyle","year":"2006","unstructured":"Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, Dispenzieri A, Katzmann JA, Melton LJ III (2006) Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 354(13):1362\u20131369","journal-title":"N Engl J Med"},{"issue":"23","key":"1799_CR109","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1056\/NEJMoa013354","volume":"346","author":"HJ Lachmann","year":"2002","unstructured":"Lachmann HJ, Booth DR, Booth SE, Bybee A, Gilbertson JA, Gillmore JD, Pepys MB, Hawkins PN (2002) Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med 346(23):1786\u20131791","journal-title":"N Engl J Med"},{"issue":"9","key":"1799_CR110","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/eurheartj\/ehr383","volume":"33","author":"PT Sattianayagam","year":"2012","unstructured":"Sattianayagam PT, Hahn AF, Whelan CJ, Gibbs SD, Pinney JH, Stangou AJ, Rowczenio D, Pflugfelder PW, Fox Z, Lachmann HJ, Wechalekar AD, Hawkins PN, Gillmore JD (2012) Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant. Eur Heart J 33(9):1120\u20131127","journal-title":"Eur Heart J"},{"issue":"3","key":"1799_CR111","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/13506129.2019.1627312","volume":"26","author":"I Concei\u00e7\u00e3o","year":"2019","unstructured":"Concei\u00e7\u00e3o I, Coelho T, Rapezzi C, Parman Y, Obici L, Gal\u00e1n L, Rousseau A (2019) Assessment of patients with hereditary transthyretin amyloidosis \u2014understanding the impact of management and disease progressio. Amyloid 26(3):103\u2013111","journal-title":"Amyloid"},{"issue":"9","key":"1799_CR112","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1136\/thx.37.9.711","volume":"37","author":"BE Griffiths","year":"1982","unstructured":"Griffiths BE, Hughes P, Dowdle R, Stephens MR (1982) Cardiac amyloidosis with asymmetrical septal hypertrophy and deterioration after nifedipine. Thorax 37(9):711\u2013712","journal-title":"Thorax"},{"issue":"36","key":"1799_CR113","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","volume":"30","author":"G Palladini","year":"2012","unstructured":"Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, Schonland S, Hegenbart U, Comenzo R, Kastritis E, Dimopoulos MA, Jaccard A, Klersy C, Merlini G (2012) New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol 30(36):4541\u20134549","journal-title":"J Clin Oncol"},{"issue":"7","key":"1799_CR114","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/bmt.2011.152","volume":"47","author":"SO Schonland","year":"2012","unstructured":"Schonland SO, Dreger P, de Witte T, Hegenbart U (2012) Current status of hematopoietic cell transplantation in the treatment of systemic amyloid light-chain amyloidosis. Bone Marrow Transplant 47(7):895\u2013905","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"1799_CR115","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1200\/JCO.2009.23.8220","volume":"28","author":"E Kastritis","year":"2010","unstructured":"Kastritis E, Wechalekar AD, Dimopoulos MA, Merlini G, Hawkins PN, Perfetti V, Gillmore JD, Palladini G (2010) Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol 28(6):1031\u20131037","journal-title":"J Clin Oncol"},{"issue":"19","key":"1799_CR116","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1182\/blood-2011-10-388462","volume":"119","author":"CP Venner","year":"2012","unstructured":"Venner CP, Lane T, Foard D, Rannigan L, Gibbs SD, Pinney JH, Whelan CJ, Lachmann HJ, Gillmore JD, Hawkins PN, Wechalekar AD (2012) Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood 119(19):4387\u20134390","journal-title":"Blood"},{"issue":"4","key":"1799_CR117","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/s41409-018-0284-4","volume":"54","author":"C Varga","year":"2019","unstructured":"Varga C, Comenzo RL (2019) High-dose melphalan and stem cell transplantation in systemic AL amyloidosis in the era of novel anti-plasma cell therapy: a comprehensive review. Bone Marrow Transplant 54(4):508\u2013518","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"1799_CR118","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, Kristen AV, Grogan M, Witteles R, Damy T, Drachman BM, Shah SJ, Hanna M, Judge DP, Barsdorf AI, Huber P, Patterson TA, Riley S, Schumacher J, Stewart M, Sultan MB, Rapezzi C (2018) Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 379(11):1007\u20131016","journal-title":"N Engl J Med"},{"issue":"3","key":"1799_CR119","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1080\/13506129.2017.1357545","volume":"24","author":"FA Barroso","year":"2017","unstructured":"Barroso FA, Judge DP, Ebede B, Li H, Stewart M, Amass L, Sultan MB (2017) Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years. Amyloid 24(3):194\u2013204","journal-title":"Amyloid"},{"issue":"1","key":"1799_CR120","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams D, Gonzalez-Duarte A, O\u2019Riordan WD, Yang CC, Ueda M, Kristen AV, Tournev I, Schmidt HH, Coelho T, Berk JL, Lin KP, Vita G, Attarian S, Plante-Bordeneuve V, Mezei MM, Campistol JM, Buades J, Brannagan TH III, Kim BJ, Oh J, Parman Y, Sekijima Y, Hawkins PN, Solomon SD, Polydefkis M, Dyck PJ, Gandhi PJ, Goyal S, Chen J, Strahs AL, Nochur SV, Sweetser MT, Garg PP, Vaishnaw AK, Gollob JA, Suhr OB (2018) Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 379(1):11\u201321","journal-title":"N Engl J Med"},{"issue":"1","key":"1799_CR121","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, Plante-Bordeneuve V, Barroso FA, Merlini G, Obici L, Scheinberg M, Brannagan TH III, Litchy WJ, Whelan C, Drachman BM, Adams D, Heitner SB, Conceicao I, Schmidt HH, Vita G, Campistol JM, Gamez J, Gorevic PD, Gane E, Shah AM, Solomon SD, Monia BP, Hughes SG, Kwoh TJ, McEvoy BW, Jung SW, Baker BF, Ackermann EJ, Gertz MA, Coelho T (2018) Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med 379(1):22\u201331","journal-title":"N Engl J Med"},{"issue":"4","key":"1799_CR122","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","volume":"139","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, Adams D, Kristen A, Grogan M, Gonzalez-Duarte A, Maurer MS, Merlini G, Damy T, Slama MS, Brannagan TH III, Dispenzieri A, Berk JL, Shah AM, Garg P, Vaishnaw A, Karsten V, Chen J, Gollob J, Vest J, Suhr O (2019) Effects of Patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis. Circulation 139(4):431\u2013443","journal-title":"Circulation"},{"key":"1799_CR123","doi-asserted-by":"crossref","first-page":"6319","DOI":"10.2147\/DDDT.S96893","volume":"9","author":"F Aus dem Siepen","year":"2015","unstructured":"Aus dem Siepen F, Bauer R, Aurich M, Buss SJ, Steen H, Altland K, Katus HA, Kristen AV (2015) Green tea extract as a treatment for patients with wild-type transthyretin amyloidosis: an observational study. Drug Des Devel Ther 9:6319\u20136325","journal-title":"Drug Des Devel Ther"},{"issue":"3","key":"1799_CR124","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.cardfail.2019.01.006","volume":"25","author":"E Karlstedt","year":"2019","unstructured":"Karlstedt E, Jimenez-Zepeda V, Howlett JG, White JA, Fine NM (2019) Clinical experience with the use of doxycycline and ursodeoxycholic acid for the treatment of transthyretin cardiac amyloidosis. J Card Fail 25(3):147\u2013153","journal-title":"J Card Fail"},{"issue":"15","key":"1799_CR125","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1161\/CIRCULATIONAHA.119.045093","volume":"141","author":"DS Kazi","year":"2020","unstructured":"Kazi DS, Bellows BK, Baron SJ, Shen C, Cohen DJ, Spertus JA, Yeh RW, Arnold SV, Sperry BW, Maurer MS, Shah SJ (2020) Cost-effectiveness of Tafamidis therapy for transthyretin amyloid cardiomyopathy. Circulation 141(15):1214\u20131224","journal-title":"Circulation"},{"key":"1799_CR126","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2147\/CLEP.S39981","volume":"6","author":"D Real de Asua","year":"2014","unstructured":"Real de Asua D, Costa R, Galvan JM, Filigheddu MT, Trujillo D, Cadinanos J (2014) Systemic AA amyloidosis: epidemiology, diagnosis, and management. Clin Epidemiol 6:369\u2013377","journal-title":"Clin Epidemiol"},{"issue":"10","key":"1799_CR127","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1002\/lt.21817","volume":"15","author":"S Okamoto","year":"2009","unstructured":"Okamoto S, Wixner J, Obayashi K, Ando Y, Ericzon BG, Friman S, Uchino M, Suhr OB (2009) Liver transplantation for familial amyloidotic polyneuropathy: impact on Swedish patients\u2019 survival. Liver Transpl 15(10):1229\u20131235","journal-title":"Liver Transpl"},{"issue":"2","key":"1799_CR128","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/TP.0000000000001021","volume":"100","author":"OB Suhr","year":"2016","unstructured":"Suhr OB, Larsson M, Ericzon BG, Wilczek HE (2016) Survival after transplantation in patients with mutations other than Val30Met: extracts from the FAP World Transplant Registry. Transplantation 100(2):373\u2013381","journal-title":"Transplantation"},{"issue":"1","key":"1799_CR129","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1600-6143.2006.01585.x","volume":"7","author":"M Yazaki","year":"2007","unstructured":"Yazaki M, Mitsuhashi S, Tokuda T, Kametani F, Takei YI, Koyama J, Kawamorita A, Kanno H, Ikeda SI (2007) Progressive wild-type transthyretin deposition after liver transplantation preferentially occurs onto myocardium in FAP patients. Am J Transplant 7(1):235\u2013242","journal-title":"Am J Transplant"},{"issue":"9","key":"1799_CR130","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/TP.0000000000000574","volume":"99","author":"BG Ericzon","year":"2015","unstructured":"Ericzon BG, Wilczek HE, Larsson M, Wijayatunga P, Stangou A, Pena JR, Furtado E, Barroso E, Daniel J, Samuel D, Adam R, Karam V, Poterucha J, Lewis D, Ferraz-Neto BH, Cruz MW, Munar-Ques M, Fabregat J, Ikeda S, Ando Y, Heaton N, Otto G, Suhr O (2015) Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative? Transplantation 99(9):1847\u20131854","journal-title":"Transplantation"},{"issue":"5","key":"1799_CR131","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/00019052-200410000-00012","volume":"17","author":"AJ Stangou","year":"2004","unstructured":"Stangou AJ, Hawkins PN (2004) Liver transplantation in transthyretin-related familial amyloid polyneuropathy. Curr Opin Neurol 17(5):615\u2013620","journal-title":"Curr Opin Neurol"},{"issue":"1","key":"1799_CR132","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/biomedicines7010011","volume":"7","author":"H Koike","year":"2019","unstructured":"Koike H, Katsuno M (2019) Ultrastructure in transthyretin amyloidosis: from pathophysiology to therapeutic insights. Biomedicines 7(1):11. https:\/\/doi.org\/10.3390\/biomedicines7010011","journal-title":"Biomedicines"},{"issue":"8 Pt 1","key":"1799_CR133","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1046\/j.1460-9592.2001.01228.x","volume":"24","author":"G Palladini","year":"2001","unstructured":"Palladini G, Malamani G, Co F, Pistorio A, Recusani F, Anesi E, Garini P, Merlini G (2001) Holter monitoring in AL amyloidosis: prognostic implications. Pacing Clin Electrophysiol 24(8 Pt 1):1228\u20131233","journal-title":"Pacing Clin Electrophysiol"},{"issue":"1","key":"1799_CR134","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.hrthm.2013.10.026","volume":"11","author":"BC Varr","year":"2014","unstructured":"Varr BC, Zarafshar S, Coakley T, Liedtke M, Lafayette RA, Arai S, Schrier SL, Witteles RM (2014) Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis. Heart Rhythm 11(1):158\u2013162","journal-title":"Heart Rhythm"},{"issue":"18","key":"1799_CR135","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1093\/eurheartj\/ehu506","volume":"36","author":"RH Sayed","year":"2015","unstructured":"Sayed RH, Rogers D, Khan F, Wechalekar AD, Lachmann HJ, Fontana M, Mahmood S, Sachchithanantham S, Patel K, Hawkins PN, Whelan CJ, Gillmore JD (2015) A study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis. Eur Heart J 36(18):1098\u20131105","journal-title":"Eur Heart J"},{"issue":"2","key":"1799_CR136","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.hrthm.2007.10.016","volume":"5","author":"AV Kristen","year":"2008","unstructured":"Kristen AV, Dengler TJ, Hegenbart U, Schonland SO, Goldschmidt H, Sack FU, Voss F, Becker R, Katus HA, Bauer A (2008) Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death. Heart Rhythm 5(2):235\u2013240","journal-title":"Heart Rhythm"},{"issue":"7","key":"1799_CR137","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/jce.12123","volume":"24","author":"G Lin","year":"2013","unstructured":"Lin G, Dispenzieri A, Kyle R, Grogan M, Brady PA (2013) Implantable cardioverter defibrillators in patients with cardiac amyloidosis. J Cardiovasc Electrophysiol 24(7):793\u2013798","journal-title":"J Cardiovasc Electrophysiol"},{"key":"1799_CR138","doi-asserted-by":"crossref","first-page":"bcr2014206600","DOI":"10.1136\/bcr-2014-206600","volume":"2014","author":"KS Patel","year":"2014","unstructured":"Patel KS, Hawkins PN, Whelan CJ, Gillmore JD (2014) Life-saving implantable cardioverter defibrillator therapy in cardiac AL amyloidosis. BMJ Case Rep 2014:bcr2014206600","journal-title":"BMJ Case Rep"},{"issue":"12","key":"1799_CR139","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1093\/eurheartj\/ehp592","volume":"31","author":"G Lin","year":"2010","unstructured":"Lin G, Dispenzieri A, Brady PA (2010) Successful termination of a ventricular arrhythmia by implantable cardioverter defibrillator therapy in a patient with cardiac amyloidosis: insight into mechanisms of sudden death. Eur Heart J 31(12):1538","journal-title":"Eur Heart J"},{"issue":"41","key":"1799_CR140","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1093\/eurheartj\/ehv316","volume":"36","author":"SG Priori","year":"2015","unstructured":"Priori SG, Blomstrom-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, Elliott PM, Fitzsimons D, Hatala R, Hindricks G, Kirchhof P, Kjeldsen K, Kuck KH, Hernandez-Madrid A, Nikolaou N, Norekval TM, Spaulding C, Van Veldhuisen DJ (2015) 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 36(41):2793\u20132867","journal-title":"Eur Heart J"},{"issue":"12","key":"1799_CR141","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.jacc.2012.12.017","volume":"61","author":"AM Russo","year":"2013","unstructured":"Russo AM, Stainback RF, Bailey SR, Epstein AE, Heidenreich PA, Jessup M, Kapa S, Kremers MS, Lindsay BD, Stevenson LW (2013) ACCF\/HRS\/AHA\/ASE\/HFSA\/SCAI\/SCCT\/SCMR 2013 appropriate use criteria for implantable cardioverter-defibrillators and cardiac resynchronization therapy: a report of the American College of Cardiology Foundation appropriate use criteria task force, Heart Rhythm Society, American Heart Association, American Society of Echocardiography, Heart Failure Society of America, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. J Am Coll Cardiol 61(12):1318\u20131368","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"1799_CR142","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1016\/j.jacc.2017.10.054","volume":"72","author":"SM Al-Khatib","year":"2018","unstructured":"Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, Deal BJ, Dickfeld T, Field ME, Fonarow GC, Gillis AM, Granger CB, Hammill SC, Hlatky MA, Joglar JA, Kay GN, Matlock DD, Myerburg RJ, Page RL (2018) 2017 AHA\/ACC\/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 72(14):e91\u2013e220","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"1799_CR143","doi-asserted-by":"publisher","first-page":"e373","DOI":"10.1016\/j.hrthm.2019.09.019","volume":"16","author":"JA Towbin","year":"2019","unstructured":"Towbin JA, McKenna WJ, Abrams DJ, Ackerman MJ, Calkins H, Darrieux FCC, Daubert JP, de Chillou C, DePasquale EC, Desai MY et al (2019) 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy: executive summary. Heart Rhythm 16(11):e373\u2013e407. https:\/\/doi.org\/10.1016\/j.hrthm.2019.09.019","journal-title":"Heart Rhythm"},{"issue":"29","key":"1799_CR144","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1093\/eurheartj\/eht150","volume":"34","author":"M Brignole","year":"2013","unstructured":"Brignole M, Auricchio A, Baron-Esquivias G, Bordachar P, Boriani G, Breithardt OA, Cleland J, Deharo JC, Delgado V, Elliott PM, Gorenek B, Israel CW, Leclercq C, Linde C, Mont L, Padeletti L, Sutton R, Vardas PE, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Kirchhof P, Blomstrom-Lundqvist C, Badano LP, Aliyev F, Bansch D, Baumgartner H, Bsata W, Buser P, Charron P, Daubert JC, Dobreanu D, Faerestrand S, Hasdai D, Hoes AW, Le Heuzey JY, Mavrakis H, McDonagh T, Merino JL, Nawar MM, Nielsen JC, Pieske B, Poposka L, Ruschitzka F, Tendera M, Van Gelder IC, Wilson CM (2013) 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur Heart J 34(29):2281\u20132329","journal-title":"Eur Heart J"},{"issue":"6","key":"1799_CR145","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1182\/blood-2004-01-0390","volume":"104","author":"A Dispenzieri","year":"2004","unstructured":"Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, McConnell JP, Litzow MR, Gastineau DA, Tefferi A, Inwards DJ, Micallef IN, Ansell SM, Porrata LF, Elliott MA, Hogan WJ, Rajkumar SV, Fonseca R, Greipp PR, Witzig TE, Lust JA, Zeldenrust SR, Snow DS, Hayman SR, McGregor CG, Jaffe AS (2004) Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 104(6):1881\u20131887","journal-title":"Blood"},{"issue":"11","key":"1799_CR146","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1038\/leu.2012.100","volume":"26","author":"RL Comenzo","year":"2012","unstructured":"Comenzo RL, Reece D, Palladini G, Seldin D, Sanchorawala V, Landau H, Falk R, Wells K, Solomon A, Wechalekar A, Zonder J, Dispenzieri A, Gertz M, Streicher H, Skinner M, Kyle RA, Merlini G (2012) Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia 26(11):2317\u20132325","journal-title":"Leukemia"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-020-01799-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-020-01799-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-020-01799-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,11]],"date-time":"2022-12-11T18:39:19Z","timestamp":1670783959000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-020-01799-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,18]]},"references-count":146,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["1799"],"URL":"https:\/\/doi.org\/10.1007\/s00392-020-01799-3","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,18]]},"assertion":[{"value":"30 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Ali Yilmaz: speaker and consultant activities for Alnylam, Pfizer Pharma GmbH and Akcea Therapeutics; research cooperation with Philips. Johann Bauersachs: speaker and consultant activities for Pfizer Pharma GmbH. Frank Bengel: speaker and consultant activities for Siemens Healthineers, GE Healthcare, Alnylam and Pfizer Pharma GmbH. Ronny B\u00fcchel: speaker honoraria from Pfizer Pharma GmbH and GE Healthcare. Ingrid Kindermann: speaker honoraria from Akcea Therapeutics, Alnylam and Pfizer Pharma GmbH. Karin Klingel: speaker honoraria from Akcea Therapeutics, Alnylam and Pfizer Pharma GmbH. Fabian Knebel: speaker and consultant activities for Akcea Therapeutics, Alnylam and Pfizer Pharma GmbH. Benjamin Meder and Fabian aus dem Siepen: speaker honoraria from Akcea Therapeutics, Pfizer Pharma GmbH and Alnylam as well as travel grants from Pfizer Pharma GmbH. Caroline Morbach: research cooperation with the University of W\u00fcrzburg and Tomtec Imaging Systems funded by a research grant from the Bavarian Ministry of Economic Affairs, Regional Development and Energy, Germany; speakers honorarium and travel grants from Amgen, Tomtec, Orion Pharma, and Alnylam; participation in Advisory and Patient Eligibility Boards sponsored by Akcea, Alnylam, Pfizer, and EBR Systems; principal investigator in trials sponsored by Alnylam and AstraZeneca. Eike Nagel: speaker honoraria from Bayer AG and Neosoft; research cooperation with Bayer AG. Eric Schulze-Bahr: None. Norbert Frey: None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}